There is one clinical trial.
Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects. The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.
Description: Clinical Improvement is defined as the time to normalization of fever (defined as temperature <37.8 oC for 72 hours) and/or resolution of baseline sign/symptoms, without the need for symptomatic treatment Virological clearance is defined as the time to two consecutive negative COVID-19 PCR samples
Measure: Time to Clinical Improvement and/or Virological Clearance (Composite Endpoint) Time: Up to 90 daysDescription: o Defined as two consecutive negative COVID-19 PCR samples
Measure: Percentage of Virological Clearance Time: At day 14, day 21, and day 28.Description: o Defined as the need for respiratory support, vasopressor use, or corticosteroids/immunomodulation therapy
Measure: Percentage of Clinical Deterioration Time: Up to 28 days